↓ Skip to main content

Dove Medical Press

Safinamide: an add-on treatment for managing Parkinson’s disease

Overview of attention for article published in Clinical Pharmacology : Advances and Applications, April 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
46 Mendeley
Title
Safinamide: an add-on treatment for managing Parkinson’s disease
Published in
Clinical Pharmacology : Advances and Applications, April 2018
DOI 10.2147/cpaa.s137740
Pubmed ID
Authors

Thomas Müller

Abstract

Heterogeneous expression of neurotransmitter deficits results from onset and progression of Parkinson's disease. Intervals, characterized by reappearance of motor and associated certain nonmotor symptoms, determine the end of good tolerability and efficacy of oral levodopa therapy. These "OFF" states result from levodopa pharmacokinetics and disease progression-related deterioration of the central buffering capacity for fluctuations of dopamine levels. This review discusses safinamide as an add-on therapeutic agent in orally levodopa-treated patients with "OFF" phenomena. Safinamide provided beneficial effects on "OFF" symptoms in pivotal trials with doses of 50 or 100 mg once daily. Safinamide reversibly inhibits mono-amine oxidase B and declines abnormal glutamate release by modulation of potassium- and sodium ion channels. An ideal candidate for combination with safinamide is opicapone. This inhibitor of peripheral catechol-O-methyltransferase supports continuous brain delivery of levodopa and, thus, the continuous dopaminergic stimulation concept. Both compounds with their once-daily application and good tolerability may complement each other by reduction of necessary oral levodopa intakes and "OFF" times. Thus, a promising, future option will be combination of safinamide and opicapone in one formulation. It will reduce adherence issues and may complement levodopa treatment. It will probably cause less nausea and edema than a dopamine agonist/levodopa regimen.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 46 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 12 26%
Student > Master 6 13%
Researcher 4 9%
Student > Postgraduate 3 7%
Student > Ph. D. Student 2 4%
Other 4 9%
Unknown 15 33%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 7 15%
Biochemistry, Genetics and Molecular Biology 6 13%
Medicine and Dentistry 5 11%
Neuroscience 4 9%
Agricultural and Biological Sciences 2 4%
Other 5 11%
Unknown 17 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2018.
All research outputs
#15,879,822
of 25,584,565 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#100
of 179 outputs
Outputs of similar age
#192,774
of 344,304 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#1
of 3 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 179 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,304 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them